Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines

被引：79

作者：

Natchus, MG ^{[1
]}

Bookland, RG ^{[1
]}

De, B ^{[1
]}

Almstead, NG ^{[1
]}

Pikul, S ^{[1
]}

Janusz, MJ ^{[1
]}

Heitmeyer, SA ^{[1
]}

Hookfin, EB ^{[1
]}

Hsieh, LC ^{[1
]}

Dowty, ME ^{[1
]}

Dietsch, CR ^{[1
]}

Patel, VS ^{[1
]}

Garver, SM ^{[1
]}

Gu, F ^{[1
]}

Pokross, ME ^{[1
]}

Mieling, GE ^{[1
]}

Baker, TR ^{[1
]}

Foltz, DJ ^{[1
]}

Peng, SX ^{[1
]}

Bornes, DM ^{[1
]}

Strojnowski, MJ ^{[1
]}

Taiwo, YO ^{[1
]}

机构：

[1] Procter & Gamble Pharmaceut, Mason, OH 45040 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2000年 / 43卷 / 26期

关键词：

D O I：

10.1021/jm000246e

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of hydroxamates was prepared from an aminoproline scaffold and tested for efficacy as matrix metalloproteinase (MMP) inhibitors. Detailed SAR for the series is reported for five enzymes within the MMP family, and a number of inhibitors, such as compound 47, display broad-spectrum activity with sub-nanomolar potency for some enzymes. Modifications of the P1' portion of the molecule played a key role in affecting both potency and selectivity within the MMP family. Longer-chain aliphatic substituents in this region of the molecule tended to increase potency for MMP-3 and decrease potency for MMP-1, as exemplified by compounds 48-50, while aromatic substituents, as in compound 52, generated broad-spectrum inhibition. The data is rationalized based upon X-ray crystal data which is also presented. While the in vitro peroral absorption seemed to be less predictable, it tended to decrease with longer and more hydrophilic substituents. Finally, a rat model of osteoarthritis was used to evaluate the efficacy of these compounds, and a direct link was established between their pharmacokinetics and their in vivo efficacy.

引用

页码：4948 / 4963

页数：16

共 31 条

[1] Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis [J].

Ahrens, D ;

Koch, AE ;

Pope, RM ;

SteinPicarella, M ;

Niedbala, MJ .

ARTHRITIS AND RHEUMATISM, 1996, 39 (09) :1576-1587

[2] Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors [J].

Almstead, NG ;

Bradley, RS ;

Pikul, S ;

De, B ;

Natchus, MG ;

Taiwo, YO ;

Gu, F ;

Williams, LE ;

Hynd, BA ;

Janusz, MJ ;

Dunaway, CM ;

Mieling, GE .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (22) :4547-4562

[3] MMP inhibitors: experimental and clinical studies [J].

Belotti, D ;

Paganoni, P ;

Giavazzi, R .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1999, 14 (04) :232-238

[4] Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis [J].

Blaser, J ;

Triebel, S ;

Maasjosthusmann, U ;

Romisch, J ;

KrahlMateblowski, U ;

Freudenberg, W ;

Fricke, R ;

Tschesche, H .

CLINICA CHIMICA ACTA, 1996, 244 (01) :17-33

[5] Insights into MMP-TIMP interactions [J].

Bode, W ;

Fernandez-Catalan, C ;

Grams, F ;

Gomis-Rüth, FX ;

Nagase, H ;

Tschesche, H ;

Maskos, K .

INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 :73-91

[6]

BUCHMANN U, 1985, Z RHEUMATOL, V44, P100

[7]

CHEN L, 1999, J MOL BIOL, V261, P14245

[8] Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold [J].

Cheng, MY ;

De, B ;

Almstead, NG ;

Pikul, S ;

Dowty, ME ;

Dietsch, CR ;

Dunaway, CM ;

Gu, F ;

Hsieh, LC ;

Janusz, MJ ;

Taiwo, YO ;

Natchus, MG ;

Hudlicky, T ;

Mandel, M .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (26) :5426-5436

[9] Design and synthesis of piperazine-based matrix metalloproteinase inhibitors [J].

Cheng, MY ;

De, B ;

Pikul, S ;

Almstead, NG ;

Natchus, MG ;

Anastasio, MV ;

McPhail, SJ ;

Snider, CE ;

Taiwo, YO ;

Chen, LY ;

Dunaway, CM ;

Gu, F ;

Dowty, ME ;

Mieling, GE ;

Janusz, MJ ;

Wang-Weigand, S .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (03) :369-380

[10]

CLARK IM, 2000, CURR OPIN ANTIINFLAM, V2, P16

← 1 2 3 4 →